QUESTIONS AND ANSWERS
Has there been a transition in IDF leadership?
John Boyle stepped down from his role as CEO after nine years of dedicated service to IDF, including three years as CEO. John and the Boyle family have been an important cornerstone of the foundation’s legacy. He will remain a tireless advocate for the PI community.
IDF’s leadership and commitment to advocacy, education, and research to improve the lives of people affected by primary immunodeficiencies remains strong. Kathryn Stephens will serve as interim CEO until our next CEO is named.
How is the forthcoming CEO search going to be different from the 2017 search?
The search for our next CEO will be comprehensive and will entail a nationwide recruiting effort for a chief executive who can lead IDF into a better, stronger position.
When does the Board of Trustees expect to name the next CEO?
Our recruiting efforts will be conducted nationwide and will aim to identify the best possible candidates to help realize our vision to grow the impact on improving the lives of those affected by PI. Having said that, we expect to have our next CEO in place by the end of the year. In the meantime, our organization will be led by interim CEO Kathryn Stephens, a seasoned executive and strategic leader of nonprofit and social-change organizations.
April is PI Awareness month. How will this transition impact IDF’s activities?
IDF’s leadership and commitment to advocacy, education, and research to improve the lives of people affected by primary immunodeficiencies remains strong, and we will continue to be a champion for the PI community. This includes promoting and participating in PI awareness month as we have always done.
Will the June Conference still happen?
Yes. The Primary Immunodeficiency Conference will take place on June 23-26, utilizing a virtual platform, as did the 2020 IDF National Summit. Stay tuned for details; registration will open later this spring.
What is IDF’s plan for resuming in-person conferences and forums?
We recognize that our current virtual programming can make it difficult for our community to absorb all the changes to the organization in recent months. We are looking forward to resuming in-person programming as soon as it is safe to do so. In the meantime, we will continue to employ new technologies that have helped us be more accessible to more PI patients with a wider range of services.